Anthony Olszanski, MD

Anthony Olszanski, MD, RPh

Oncology Philadelphia, PA

Phase 1 early drug development for oncologic indications. Practice focus on GI malignancies/melanoma.

Office Address

Office Map
  • 333 Cottman Ave
    Medical Staff Office
    Philadelphia, PA 19111
    Phone: (215) 728-6900
    Fax: (215) 214-3229

Dr. Olszanski's Clinical Specialties & Interests

  • Oncology: General Oncology, Gastrointestinal Cancer, Melanoma
  • Clinical Interests: Gastrointestinal Neoplasms; Clinical Trials as Topic; Pancreatic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Phase 1 Early Drug Development

Dr. Olszanski's Faculty Appointments & Work History

  • Associate ProfessorFox Chase Cancer Center
    Philadelphia, PA
    Director, Phase 1 Program
  • Clinical Leader, DirectorPfizer Oncology
    New London, CT
  • Staff Emergency Room PhysicianMount Ascutney Medical Center
    Windsor, VT
  • Clinical Pharmacology/Toxicology Fellowship, Oncology Phase I ProgramDartmouth Hitchcock Medical Center
    Lebanon, NH
    Internal Medicine Residency, Department of Medicine (1996-1999); Hematology/Oncology Fellowship (1999-2002); Instructor of Medicine (2002-2004); Clinical Pharmacology/Toxicology Fellowship (2002-2004)
  • Per-Diem PharmacistRobert Wood Johnson University Hospital
    New Brunswick, NJ
    Staff Pharmacist (1990-1992); Per-Diem Pharmacist (1992-1996)
  • Staff Pharmacist/Graduate InternSomerset Medical Center
    Somerset, NJ

Dr. Olszanski's Education & Medical Training

  • Dartmouth-Hitchcock Medical CenterDartmouth-Hitchcock Medical CenterFellowship, Clinical Pharmacology
  • Dartmouth-Hitchcock Medical CenterDartmouth-Hitchcock Medical CenterFellowship, Hematology/Oncology
  • Dartmouth-Hitchcock Medical CenterDartmouth-Hitchcock Medical CenterResidency, Internal Medicine
  • Rutgers New Jersey Medical SchoolRutgers New Jersey Medical SchoolMedical School
  • University of MontanaUniversity of MontanaOther Training, B.S, Pharmacy

Dr. Olszanski's Certifications & Licensure

  • PA State Medical LicensePA State Medical License2009 - 2014
  • American Board of Clinical PharmacologyAmerican Board of Clinical PharmacologyClinical Pharmacology, 2008, Current
  • American Board of Internal MedicineAmerican Board of Internal MedicineInternal Medicine, 1999
  • American Board of Internal MedicineAmerican Board of Internal MedicineMedical Oncology, 2003, Current

Dr. Olszanski's Awards, Honors, & Recognition

  • American Association for Cancer ResearchAccelerating Anticancer Agent Development and ValidationAmerican Association for Cancer Research, 2006
  • American Association for Cancer ResearchMethods in Clinical Cancer ResearchAmerican Association for Cancer Research, 2003
  • American Association for Cancer ResearchMolecular Biology in Clinical OncologyAmerican Association for Cancer Research, 2002
  • Register to See 7 More...

Dr. Olszanski's Clinical Trials

Dr. Olszanski's Publications & Presentations

PubMed | Citations by Web of Science®

Journal Articles

  • Phase I dose-escalation study of LCL161, an oral IAP inhibitor, in patients with advanced solid tumors.Infante JR, Dees EC, Olszanski AJ, JCO
  • Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: A Phase II trial.Slingluff CL, Petroni GR, Molhoek KR, Olszanski AJ, CCR
  • Phase I study of axitinib combined with paclitaxel, docetaxel, or capecitabine in patients with advanced solid tumors.Martin LP, Kozloff MF, Herbst RS et al. and Olszanski AJ, British Journal of Cancer, 107; 1268-1276
  • Register to See 4 More...


  • Dose-escalation Phase 1 study of cabazitaxel (Cbz) + gemcitabine (Gem) in patients (pts) with metastatic or unresectable advanced solid malignancy.Rixe O, Puzanov I., LoRusso P, et al and Olszanski AJ, ESMO (2012) Abstract 497P
  • Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: Phase II trial with correlative studies.Slingluff CL, et al and Olszanski AJ, ASCO (2012) Abstract 8530
  • Phase 1 and pharmacokinetic (PK)/pharmacodynamic (PD) study of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.Faivre S, Olszanski AJ, ASCO (2012) Abstract 2554
  • Register to See 16 More...

Grant Support

  • Cancer Genome Institute Clinical Research Pilot Grant
    Cancer Genome Institute Clinical Research Pilot GrantFox Chase Cancer Center
    2013 - Present


  • Research Reivew Committee, FCCCMember2009 - Present
  • Pharmacy & Therapeutics Committee, FCCCChair2012 - Present
  • American Board of Clinical Pharmacology, Credentials CommitteeChair2011 - Present
  • FCCC Cancer Genome InstituteSenior Medical Advisor2012 - Present
  • FCCC Genomic Advisory BoardChair2012 - Present
  • National Comprehensive Cancer Network, Melanoma PanelMember2010 - Present
  • Data Safety Monitoring Board, FCCCMember2012 - Present
  • NCCN Investigator Steering CommitteeMember2012 - Present

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • AmeriHealth Direct POS
  • Amerihealth HMO
  • AmeriHealth PPO
  • BCBS Blue Card PPO
  • CIGNA Open Access
  • Great West PPO
  • Humana ChoiceCare Network PPO
  • IBC Keystone HMO / POS
  • IBC Personal Choice PPO
  • Multiplan PHCS PPO
  • Multiplan PPO
  • QualCare HMO
  • QualCare PPO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO

Physicians, view Dr. Olszanski's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV